AU2013295855A1 - Prediction of treatment response to JAK/STAT inhibitor - Google Patents

Prediction of treatment response to JAK/STAT inhibitor Download PDF

Info

Publication number
AU2013295855A1
AU2013295855A1 AU2013295855A AU2013295855A AU2013295855A1 AU 2013295855 A1 AU2013295855 A1 AU 2013295855A1 AU 2013295855 A AU2013295855 A AU 2013295855A AU 2013295855 A AU2013295855 A AU 2013295855A AU 2013295855 A1 AU2013295855 A1 AU 2013295855A1
Authority
AU
Australia
Prior art keywords
jak
biomarkers
expression
stat
cish
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013295855A
Other languages
English (en)
Inventor
Alexander CAO
Michael Morrissey
Michael Palmer
Dmitriy SONKIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48906529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013295855(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2013295855A1 publication Critical patent/AU2013295855A1/en
Priority to AU2017204894A priority Critical patent/AU2017204894A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2013295855A 2012-07-27 2013-07-24 Prediction of treatment response to JAK/STAT inhibitor Abandoned AU2013295855A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017204894A AU2017204894A1 (en) 2012-07-27 2017-07-14 Prediction of treatment response to JAK/STAT inhibitor

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261676484P 2012-07-27 2012-07-27
US61/676,484 2012-07-27
US201361769271P 2013-02-26 2013-02-26
US61/769,271 2013-02-26
US201361829327P 2013-05-31 2013-05-31
US61/829,327 2013-05-31
PCT/US2013/051824 WO2014018632A1 (en) 2012-07-27 2013-07-24 Prediction of treatment response to jak/stat inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017204894A Division AU2017204894A1 (en) 2012-07-27 2017-07-14 Prediction of treatment response to JAK/STAT inhibitor

Publications (1)

Publication Number Publication Date
AU2013295855A1 true AU2013295855A1 (en) 2015-02-12

Family

ID=48906529

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013295855A Abandoned AU2013295855A1 (en) 2012-07-27 2013-07-24 Prediction of treatment response to JAK/STAT inhibitor
AU2017204894A Abandoned AU2017204894A1 (en) 2012-07-27 2017-07-14 Prediction of treatment response to JAK/STAT inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017204894A Abandoned AU2017204894A1 (en) 2012-07-27 2017-07-14 Prediction of treatment response to JAK/STAT inhibitor

Country Status (18)

Country Link
US (1) US20150299796A1 (https=)
EP (1) EP2877596A1 (https=)
JP (1) JP2015526074A (https=)
KR (1) KR20150038241A (https=)
CN (1) CN104508149A (https=)
AU (2) AU2013295855A1 (https=)
BR (1) BR112015001521A2 (https=)
CA (1) CA2880198A1 (https=)
CL (1) CL2015000192A1 (https=)
HK (1) HK1205198A1 (https=)
IL (1) IL236897A0 (https=)
MX (1) MX2015001269A (https=)
PH (1) PH12015500169A1 (https=)
RU (1) RU2015106714A (https=)
SG (1) SG11201500261VA (https=)
TN (1) TN2015000019A1 (https=)
TW (1) TW201409030A (https=)
WO (1) WO2014018632A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
HK1248603A1 (zh) 2015-03-10 2018-10-19 Aduro Biotech, Inc. 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN106544414A (zh) * 2016-10-09 2017-03-29 广州泰诺迪生物科技有限公司 一种检测肺癌脑转移样本中stat3和lck的方法
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN107137701B (zh) * 2017-05-07 2020-07-14 山东兴瑞生物科技有限公司 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US20060194275A1 (en) * 2001-04-13 2006-08-31 Incyte Corporation Transporter and ion channels
WO2010048123A2 (en) * 2008-10-20 2010-04-29 Eckhardt S Gail Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CN102459258B (zh) * 2009-06-05 2015-11-25 赛福伦公司 1,2,4-三唑并[1,5a]吡啶衍生物的制备和用途
WO2012071612A1 (en) * 2010-12-03 2012-06-07 Ym Biosciences Australia Pty Ltd Treatment of jak2-mediated conditions

Also Published As

Publication number Publication date
JP2015526074A (ja) 2015-09-10
RU2015106714A (ru) 2016-09-20
CL2015000192A1 (es) 2015-06-26
MX2015001269A (es) 2015-05-08
IL236897A0 (en) 2015-03-31
TN2015000019A1 (en) 2016-06-29
KR20150038241A (ko) 2015-04-08
US20150299796A1 (en) 2015-10-22
PH12015500169A1 (en) 2015-03-16
EP2877596A1 (en) 2015-06-03
WO2014018632A1 (en) 2014-01-30
BR112015001521A2 (pt) 2017-11-07
SG11201500261VA (en) 2015-02-27
CN104508149A (zh) 2015-04-08
AU2017204894A1 (en) 2017-08-03
CA2880198A1 (en) 2014-01-30
TW201409030A (zh) 2014-03-01
HK1205198A1 (en) 2015-12-11

Similar Documents

Publication Publication Date Title
AU2013295855A1 (en) Prediction of treatment response to JAK/STAT inhibitor
EP2715366B1 (en) Biomarkers for hedgehog inhibitor therapy
JP7777359B2 (ja) 融合遺伝子及び／又はエクソンスキッピングにより生ずる転写産物を検出するためのプローブ及び方法
EP2711433B1 (en) Method for predicting effectiveness of angiogenesis inhibitor
EP2865262A1 (en) Method for preparing patient-specific glioblastoma animal model, and use thereof
JP2020503850A (ja) 腫瘍抑制ｆｏｘｏ活性を酸化ストレスから区別する方法
CN109837340B (zh) 用于肺癌无创诊断的外周血基因标记物
Zhu et al. Cuprotosis clusters predict prognosis and immunotherapy response in low-grade glioma
WO2014190927A1 (zh) 胰腺神经内分泌肿瘤易感基因位点及检测方法和试剂盒
US20120157342A1 (en) Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
EP2451972B1 (en) Methods of classifying biological samples for predicting response to tyrosine kinase inhibitor treatment
KR102325356B1 (ko) 유사유전자를 이용한 신경교종의 악성도 진단용 조성물 및 이의 이용
de Leng et al. PATH-11. DESIGNING A DIAGNOSTIC FGFR3-TACC3 FUSION ASSAY USING RT-PCR FOR GLIOBLASTOMA MULTIFORME PATIENTS
Craddock et al. Genomic pathology of lung cancer
Silveira Scrideli CA, Carlotti Jr CG, Okamoto OK, Andrade VS, Cortez MA, Motta FJ, Lucio-Eterovic AK, Neder L, Rosemberg S, Oba-Shinjo...
NZ617421B2 (en) Biomarkers for hedgehog inhibitor therapy

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted